Dr. Talia Cohen Solal, co-founder and CEO of Israeli health-tech firm NeuroKaire, speaks with B'nai B'rith CEO Dan Mariaschin about how her company combines cutting-edge stem cell technology with artificial intelligence (AI) software to better match drugs to patients. She also explores NeuroKaire's (formerly known as Genetika+) collaboration on a promising new Alzheimer’s treatment.
👉 *SUBSCRIBE NOW* to the B'nai B'rith YouTube channel: [ Ссылка ]
🎧 *SUBSCRIBE to the B'nai B'rith Podcast*
• Apple Podcasts: [ Ссылка ]
• Spotify: [ Ссылка ]
✅ *FOLLOW B'nai B'rith:*
Twitter/X: [ Ссылка ]
Facebook: [ Ссылка ]
Instagram: [ Ссылка ]
Threads: [ Ссылка ]
*About Dr. Talia Cohen Solal*
Dr. Talia Cohen Solal co-founded Genetika+ (now NeuroKaire) in 2018 with Dr. Daphna Laifenfeld. Currently the CEO of NeuroKaire, she holds an MA in neuroscience from the University of Oxford, a PhD from University College London, and completed a fellowship at Columbia University. Throughout her career, she has secured $25 million through eight grants and three venture capital rounds, published 10 academic papers, and filed three patents, all in the field of neuroscience.
*NeuroKaire*
[ Ссылка ]
#AI #Health #Interview #Alzheimers #ArtificialIntelligence #Conversation #DrugDiscovery #Healthcare #HealthTech #Innovation #Interview #Israel #Medicine #Podcast #Solutions #Tech #Watch #YT #YTVideo
